两种胰岛素强化治疗方案在2型糖尿病合并恶性肿瘤患者放化疗期的对比研究

摘要

目的 比较甘精胰岛素联合门冬胰岛素(G+A)与门冬胰岛素30多次皮下注射(MSII)治疗2型糖尿病合并恶性肿瘤患者化疗及放疗期的疗效及安全性.方法 将71例患者随机分为两组:G+A组36例,MSII组35例,比较两组患者治疗前、后血糖变化、血糖达标时间、胰岛素用量、低血糖发生率及放化疗并发症的发生率.结果 G+A 组血糖控制效果优于MSII组(P<0.01),低血糖及放化疗并发症发生率低于MSII组(P<0.01),血糖达标时间较MSII组缩短(P<0.01).结论 G+A治疗2型糖尿病合并恶性肿瘤患者化疗及放疗期的血糖控制平稳,安全,达标迅速.%Objective To compare the efficacy and safety of insulin glargine united with Insulin aspart(G + A) with multiple subcutaneous injections by premixed insulin aspart 30(MSII) in radiotherapy and chemotherapy of type 2 diabetes with malignant tumor. Methods Seventy-one patients were randomly divided into G+ A group and MSII group. We compared blood glucose level before and after treatment,the time needed for the same glycemia control,the dose of insulin for daily use,frequency of hypog yce-mia and the incidence of complication. Results The blood glucose was controlled better in G+ A group than MSII group(P< 0. 01) , frequency of hypog ycemia and the incidence of complication were all significantly lower in G +A group than MSII group (P<0. 01) , the time needed for the same glycemia control was significantly shorter in G +A group than MSII group(P<0. 01). Conclusion The blood glucose is controlled steadily, safely and quickly by insulin glargine united with Insulin aspartin in radiotherapy and chemotherapy of type 2 diabetes with malignant tumor.